Loading
Surgeon-scientist who showed the gut microbiome shapes response to immunotherapy and led early neoadjuvant melanoma trials.
Jennifer Wargo led the 2018 Science paper showing that gut microbiome composition predicts response to PD-1 blockade in melanoma patients, alongside parallel work from Gustave Roussy and Chicago that founded microbiome-directed immuno-oncology. She led one of the first randomised neoadjuvant immunotherapy trials in melanoma and co-leads the International Neoadjuvant Melanoma Consortium. Her laboratory now studies diet, fibre and microbiome modulation.
| Title | Journal | Year |
|---|---|---|
| Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients | Science | 2018 |
| Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma | Nature Medicine | 2018 |
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors and the tags melanoma, neoadjuvant.
Shares MD Anderson Cancer Center, Ipilimumab, Nivolumab, Immune checkpoint inhibitors and the tag neoadjuvant.
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors and the tag melanoma.
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Melanoma, Immune checkpoint inhibitors and the tags melanoma, neoadjuvant.
Shares Ipilimumab, Nivolumab, Immune checkpoint inhibitors.
Shares MD Anderson Cancer Center, Ipilimumab, Nivolumab, Melanoma and the tag melanoma.